Investigating the Tumour Immune Response of Radiotherapy
This study aims to investigate immune changes which occur before and following standard radiotherapy in a range of tumour types. We will collect tissue and blood samples before and after radiation treatment from participants across six cancer types: cervical, rectal, Head and Neck cancer, nodal non-Hodgkin lymphoma, cutaneous lymphoma and cutaneous squamous cell carcinoma/ basal cell carcinoma.
• Histologically confirmed cancer, Stage I-IV, in one of the following: Cervical, rectal, nodal Non-Hodgkin lymphoma, cutaneous lymphoma, Head \& neck cancer
• Diagnostic/pre-treatment biopsy confirmed suitable for translational research \*
• Performance status - ECOG 0-2 (Refer to appendix 1), ECOG 3 allowed for arm F (unrelated to underlying cancer) as this group of patients often have ECOG 3 due to age and comorbidities.
• Age ≥ 18; no upper age limit.
• Participant considered suitable for radiotherapy
• Before participant registration, written informed consent must be given according to GCP and national regulations.
• \*Pre-treatment biopsy must be from the gross tumour volume within the planned radiation field and must also:
• Have been formalin fixed for \>12h and \<72h
• Have tumour tissue and morphology confirmed by H\&E staining
• Contain sufficient tumour cells (approximately 100)